Smart & Biggar successfully represented Boehringer Ingelheim in a s. 6(1) action under the Patented Medicines (Notice of Compliance) Regulations regarding the use of nintedanib in the prevention or treatment of idiopathic pulmonary fibrosis.
Read more about this case via our article "Boehringer Ingelheim succeeds in nintedanib PMNOC action against JAMP".
Client Success
-
Loblaws Inc v Pampered Chef et al
2021 FCA 29Successfully represented Pampered Chef et al before the FCA in having affirmed the trial decision dismissing allegations of trademark infringement brought by Canada’s largest retailer.Read More -
Nova Chemicals Corporation v Dow Chemical Company
2022 SCC 43Smart & Biggar successfully represented Dow Chemical before the Supreme Court of Canada, affirming the largest reported Canadian patent infringement award in history including the first time that ...Read More -
Tekna Plasma Systems Inc v AP&C Advanced Powders & Coatings Inc
2024 FC 871Smart & Biggar successfully represented Tekna Plasma Systems (Tekna), the plaintiff in this action.Read More